Business Description
BioLife Solutions Inc
NAICS : 339113
SIC : 3841
ISIN : US09062W2044
Total Employee Number:
155Description
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.24 | |||||
Equity-to-Asset | 0.94 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | 2.46 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 36.98 | |||||
Beneish M-Score | -1.65 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 3.8 | |||||
3-Year EPS without NRI Growth Rate | -31.1 | |||||
3-Year Book Growth Rate | -3.2 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 19.35 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 29.24 | |||||
9-Day RSI | 41.4 | |||||
14-Day RSI | 50.31 | |||||
3-1 Month Momentum % | 29.93 | |||||
6-1 Month Momentum % | 85.54 | |||||
12-1 Month Momentum % | 30.77 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 9.69 | |||||
Quick Ratio | 7.14 | |||||
Cash Ratio | 5.91 | |||||
Days Inventory | 302.9 | |||||
Days Sales Outstanding | 37.32 | |||||
Days Payable | 27.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4 | |||||
Shareholder Yield % | 0.74 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 63.88 | |||||
Operating Margin % | 2.9 | |||||
Net Margin % | 56.39 | |||||
EBITDA Margin % | 6.23 | |||||
FCF Margin % | -2.17 | |||||
OCF Margin % | 16.41 | |||||
ROE % | 15.54 | |||||
ROA % | 14.26 | |||||
ROIC % | 0.95 | |||||
ROC (Joel Greenblatt) % | 5.45 | |||||
ROCE % | 0.78 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 30.19 | |||||
Forward PE Ratio | 103.91 | |||||
PE Ratio without NRI | 35.73 | |||||
PS Ratio | 16.89 | |||||
PB Ratio | 4.08 | |||||
Price-to-Tangible-Book | 8.24 | |||||
Price-to-Operating-Cash-Flow | 103.31 | |||||
EV-to-EBIT | 552.37 | |||||
EV-to-Forward-EBIT | 17.55 | |||||
EV-to-EBITDA | 256.88 | |||||
EV-to-Forward-EBITDA | 76.22 | |||||
EV-to-Revenue | 16.01 | |||||
EV-to-Forward-Revenue | 12.13 | |||||
EV-to-FCF | -737.07 | |||||
Price-to-GF-Value | 1.15 | |||||
Price-to-Projected-FCF | 6.28 | |||||
Price-to-Median-PS-Value | 1.34 | |||||
Price-to-Graham-Number | 3.63 | |||||
| Price-to-Net-Current-Asset-Value | 15.97 | |||||
| Price-to-Net-Cash | 31.38 | |||||
Earnings Yield (Greenblatt) % | 0.18 | |||||
FCF Yield % | -0.13 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BLFS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BioLife Solutions Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 102.818 | ||
| EPS (TTM) ($) | 1.16 | ||
| Beta | 1.7946 | ||
| 3-Year Sharpe Ratio | 0.91 | ||
| 3-Year Sortino Ratio | 1.61 | ||
| Volatility % | 43.51 | ||
| 14-Day RSI | 50.31 | ||
| 14-Day ATR ($) | 1.032365 | ||
| 20-Day SMA ($) | 36.0345 | ||
| 12-1 Month Momentum % | 30.77 | ||
| 52-Week Range ($) | 17.86 - 38.1 | ||
| Shares Outstanding (Mil) | 48.92 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BioLife Solutions Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BioLife Solutions Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-26 16:30 | In 169 days | ||
| Annual report for 2026 | 2027-02-26 | In 168 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-26 | In 168 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-06 16:30 | In 57 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 56 days | ||
| General meeting for 2026 | 2026-09-10 09:00 | 34.93 (-0.23%) | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 33.80 (+3.78%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 16:30 | 21.75 (+0.42%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 21.75 (+0.42%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-26 16:30 | 22.47 (-1.71%) |
Show
Entries
BioLife Solutions Inc Frequently Asked Questions
What is BioLife Solutions Inc(BLFS)'s stock price today?
The current price of BLFS is $35.02. The 52 week high of BLFS is $38.10 and 52 week low is $17.86.
When is next earnings date of BioLife Solutions Inc(BLFS)?
The next earnings date of BioLife Solutions Inc(BLFS) is 2026-11-06 Est..
Does BioLife Solutions Inc(BLFS) pay dividends? If so, how much?
BioLife Solutions Inc(BLFS) does not pay dividend.
Guru Commentaries on NAS:BLFS
Prosper Stars Stripes
Bullish
2025 Q4
What the manager wrote
We added BioLife Solutions (BLFS) back into the portfolio as the company has undergone a significant transformation under current CEO Roderick de Greef. The previous acquisition strategy diluted the company's core strengths, but the focus on high-quality products has resulted in a cleaner business model. BioLife's cornerstone product, biopreservation media, is experiencing high growth rates and exceptional margins, particularly in the manufacturing of cell-based therapies, which is expected to grow over 20% annually over the next five years. Given the recent underperformance of healthcare stocks, we see a compelling long opportunity with 20%-plus top-line growth and meaningful margin expansion driving rapid EBITDA growth.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers